Jennifer M. Tursi
Endo Pharmaceuticals (United States) · 33 works · 4,286 citations · h-index 15
Top works
- First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
- Derivation of neutralizing monoclonal antibodies to human rotaviruses and evidence that an immunodominant neutralization site is shared between serotypes 1 and 3
- Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014
- First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)
- Phase II study of sunitinib as second-line treatment for advanced gastric cancer
- Dose-Intensive Epirubicin-Based Chemotherapy Is Superior to an Intensive Intravenous Cyclophosphamide, Methotrexate, and Fluorouracil Regimen in Metastatic Breast Cancer: A Randomized Multinational Study
- Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial
- Overall and Intracranial (Ic) Efficacy Results and Time to Symptom Deterioration in Profile 1014: 1St-Line Crizotinib Vs Pemetrexed - Platinum Chemotherapy (Ppc) in Patients (Pts) with Advanced Alk-Positive Non-Squamous Non-Small Cell Lung Cancer (Nsclc)
- Production and characterization of neutralizing monoclonal antibody to a human rotavirus strain with a "super-short" RNA pattern
- Real‐World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men
- Brostallicin (PNU-166196) – a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells
- Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET).
- Blood glutathione as a surrogate marker of cancer tissue glutathione S-transferase activity in non-small cell lung cancer and squamous cell carcinoma of the head and neck
- A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer
- Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.
- Comparative Studies of UV-induced DNA Cleavage by Analogues of iodoHoechst 33258
- A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer
- Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo.
- 3542 POSTER Preliminary results from a phase II study of sunitinib as second-line treatment for advanced gastric cancer
- Phase I study to evaluate the safety and efficacy of sunitinib in combination with FOLFIRI in treatment-naïve metastatic colorectal cancer (mCRC)